DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of “Hold” by Analysts

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has earned an average rating of “Hold” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $13.4167.

A number of research firms recently issued reports on XRAY. Barclays dropped their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Thursday, June 4th. UBS Group reduced their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Citigroup assumed coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price for the company. Mizuho lowered their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings downgraded shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th.

Insiders Place Their Bets

In related news, Director Michael J. Barber bought 15,175 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the purchase, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $101,200. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 35,160 shares of company stock worth $351,179 in the last three months. Corporate insiders own 0.46% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Several large investors have recently bought and sold shares of the stock. Southpoint Capital Advisors LP acquired a new position in shares of DENTSPLY SIRONA in the first quarter valued at about $116,000,000. AQR Capital Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the period. Armistice Capital LLC lifted its holdings in shares of DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $12.78 on Tuesday. DENTSPLY SIRONA has a 52-week low of $9.40 and a 52-week high of $17.09. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The firm’s fifty day moving average is $10.62 and its 200 day moving average is $11.69. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -4.06, a PEG ratio of 1.46 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts forecast that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.